ArticleCancer medicine2023

Cost-effectiveness of first-line versus second-line use of domestic anti-PD-1 antibody sintilimab in Chinese patients with advanced or metastatic squamous non-small cell lung cancer.

Rihua Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.